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ABSTRACT
Introduction Trauma can play an important role in the 
development of psychosis, yet no studies have investigated 
whether a trauma- focused psychological therapy could 
prevent the onset of psychosis in people at high risk of 
developing this condition. This study aims to establish 
whether it would be feasible to conduct a multicentre 
randomised controlled trial (RCT) to investigate the clinical 
and cost- effectiveness of eye movement desensitisation 
and reprocessing (EMDR) therapy to prevent the onset of 
psychosis in people with an at- risk mental state (ARMS).
Methods/analysis This is a single- arm trial with a nested 
qualitative study where all participants (target n=20) 
will be offered EMDR. Eligible participants are those who 
meet criteria for ARMS; have experienced a traumatic 
event before the onset of ARMS symptomatology; and 
have at least one symptom of post- traumatic stress 
disorder (PTSD). Participants will be followed up at 4, 
8 and 12 months after the baseline assessment. The 
primary outcome measure is transition to psychosis, 
and secondary outcome measures include severity of 
psychotic symptoms, PTSD, depression, anxiety, impaired 
functioning, health status and resource use. The analysis 
will aim to establish the rates of recruitment and retention 
for a large- scale RCT. Interviews with therapists and 
patients will explore their views of the study and their 
experiences of delivering or receiving EMDR.
Ethics and dissemination This protocol has been 
approved by the South West- Cornwall and Plymouth 
Research Ethics Committee (Reference 18/SW/0037). 
Findings will be disseminated through journal publications, 
conference presentations and meetings with service 
users, their families, mental health professionals and 
commissioners.
Trial registration number ISRCTN31976295.
INTRODUCTION
Psychotic illnesses are one of the leading 
causes of disability worldwide.1 The onset of 
psychosis is often preceded by a prodromal 
phase, known as an at- risk mental state 
(ARMS) for psychosis, which is characterised 
by a series of non- specific or attenuated 
psychotic symptoms.2 Approximately 22% of 
ARMS individuals will transition to psychosis 
within 1 year and 36% of them within 3 years.3
Various interventions have been used for 
the prevention of psychosis, but there is 
still limited evidence on the effectiveness of 
these approaches. Clinical guidelines recom-
mend cognitive–behavioural therapy (CBT) 
as a first- line treatment.4 However, while a 
meta- analysis of randomised controlled trials 
(RCT) showed that CBT has a moderate 
effect on transition to psychosis at 12 months 
of follow- up (relative risk (RR) 0.64, 95% 
CI 0.44 to 0.93), the evidence was of low to 
moderate quality and the effect was not main-
tained over the longer term (18 months: RR 
0.55, 95% CI 0.25 to 1.19).5
Exposure to trauma is two to three times 
more common in ARMS or psychosis than in 
controls,6–8 and post- traumatic stress disorder 
(PTSD) is also common, although not usually 
detected.9 Despite strong evidence showing 
that trauma is a key factor in the development 
Strengths and limitations of this study
 ► This is the first study to investigate the feasibility 
of conducting a large multicentre randomised con-
trolled trial (RCT) of eye movement desensitisation 
and reprocessing (EMDR) for the prevention of psy-
chosis in people with at- risk mental state.
 ► The study includes qualitative work to explore ther-
apists and patients’ views of the treatment offered/
received.
 ► Therapy sessions follow an EMDR protocol specifi-
cally designed for people with psychosis.
 ► The decision to change the study design to a single- 
arm trial may limit our ability to draw robust conclu-
sions about recruiting to an RCT.
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of psychosis,10–12 no studies have yet investigated whether 
a trauma- focused therapy could prevent the onset of 
psychosis in ARMS.
Eye movement desensitisation and reprocessing 
(EMDR) is a trauma- focused therapy that has compa-
rable efficacy to trauma- focused CBT (TF- CBT) in 
treating PTSD.13–16 However, the two forms of therapy 
are different. While TF- CBT seeks to directly identify 
and restructure the negative beliefs, EMDR does this 
indirectly, relying more on the integration of emotional, 
cognitive, sensory, physical and contextual information to 
allow adaptive processing of traumatic memories. Unlike 
TF- CBT, EMDR does not require patients to give a detailed 
description of the trauma, which may be distressing. Also, 
unlike TF- CBT, EMDR does not involve homework, which 
may make it more suitable for people with a disorganised 
lifestyle, such as those with ARMS.
To date, there has been only one RCT comparing 
EMDR with treatment as usual (TAU) in patients with 
comorbid psychosis and PTSD. This study showed that 
EMDR improved PTSD, and also reduced paranoid 
delusions, but did not reduce auditory hallucinations at 
6 months of follow- up.17 However, the EMDR protocol 
did not specifically target psychotic symptoms. Further-
more, most participants had chronic forms of psychosis 
and hence psychotic symptoms might have been less 
amenable to treatment than more recent onset symptoms 
present in ARMS subjects.
Objectives
The overarching aim of this study is to establish whether 
it would be feasible to conduct a large multicentre RCT 
to evaluate the clinical and cost- effectiveness of EMDR to 
prevent the onset of psychosis in people with an ARMS. 
The study has the following objectives:
1. To estimate the rate of recruitment and retention to 
inform the large- scale RCT.
2. To refine the eligibility criteria, screening and recruit-
ment procedures.
3. To optimise the EMDR protocols and learn about the 
factors which affect the implementation of EMDR.
4. To explore patients and therapists’ views of EMDR as a 
treatment for ARMS.
5. To investigate patients and therapists’ views of the 
study design and study materials.
6. To understand what TAU consists of for patients with 
ARMS.
METHODS AND ANALYSIS
Study design
The study consists of a single- arm feasibility trial with 
a nested qualitative study, and is conducted in collabo-
ration with the Early Intervention (EI) teams from the 
Avon and Wiltshire Mental Health Partnership NHS Trust 
(AWP). All participants will be offered EMDR, and will be 
assessed at baseline, 4, 8 and 12 months of follow- up as 
described below.
The study design outlined is the final version of the trial 
protocol. The original protocol was changed as a result 
of low recruitment. Recruitment challenges are described 
later.
Inclusion and exclusion criteria
Inclusion criteria
 ► Aged 16 years or over who are at risk of psychosis (as 
defined in the Comprehensive Assessment of At- Risk 
Mental States (CAARMS)).2
 ► Presence of at least one positive symptom of psychosis 
(perceptual abnormality, unusual thought content, 
non- bizarre ideas or disorganised speech) scored ≥3 
on CAARMS.
 ► History of traumatic experience as defined in Inter-
national Classification of Diseases 10th Revision (ICD-
10) F43.1, occurring prior to onset of first positive 
symptom.
 ► Presence of one or more symptoms of reliving, avoid-
ance, hyperarousal or cognitive distortions in relation 
to the traumatic experience (assessed using the PTSD 
Checklist for DSM-5 (PCL-5)) during the last month.18
Exclusion criteria
 ► History of treated or untreated psychotic illness or 
learning disability.
 ► Currently taking antipsychotics.
 ► Currently receiving psychological therapy.
 ► Completed a trauma- focused psychological therapy in 
the last 2 years.
 ► Insufficient fluency in English.
 ► Lacking mental capacity to provide valid informed 
consent.
Recruitment procedure
Participants will be identified via two routes.
EI services
Researchers will identify clinical teams who are willing to 
identify potential participants via the following routes:
A. During routine clinic appointments—clinicians will 
introduce the study to patients who have met ARMS 
criteria within the past 12 months. Interested patients 
will be asked to complete section 1 of an Expression 
of Interest (EOI) form, and to provide their contact 
details. Completed EOI forms will be returned to the 
research team by secure email. A member of the re-
search team will telephone interested individuals 
and, if the individual is willing to take part, agree a 
time and place for the researcher to meet with them 
to complete the eligibility assessment. Following the 
telephone call, the researcher will post the individual 
a full participant information sheet and a letter con-
firming the appointment.
Individuals who do not want to hear more about the 
study will be asked to complete section 2 of the EOI 
form, which asks for information on age, gender, rea-
sons for non- participation and willingness to take part 
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in a short interview (see ‘qualitative data collection’ for 
more details).
B. Postal or telephone invitations from clinicians—if cli-
nicians do not introduce the study to patients during 
the appointment, they will post patients with ARMS 
a brief information sheet about the study, an EOI 
form and a stamped addressed envelope. Clinicians 
may also introduce the study to patients over the tele-
phone. If the patients are interested, the clinician will 
ask the patients for permission to share their contact 
details with the research team. The clinician will then 
fill in the ‘Phone permission to contact’ form and will 
email it to the research team. Recruitment will then 
proceed as outlined in (A).
C. Postal invitations sent out by National Institute for 
Health Research (NIHR) Clinical Research Network 
Clinical Studies Officers (CSO)—CSOs will prescreen 
potential participants using the electronic patient re-
cord system (RiO), and liaise with the care team re-
garding potentially eligible patients who will then be 
sent a brief information sheet and details on how to 
contact the research team if they are interested in the 
study. Patients who do not reply will be followed up 
by telephone by the CSO within a week of receiving 
the documents. If the patient is interested in the study, 
the CSO will take permission over the phone to share 
their contact details with the research team. Once the 
research team have received contact details, recruit-
ment will proceed as outlined in (A).
Everyone included within AWP
‘Everyone Included’ is a standard approach to research in 
AWP, whereby service users are routinely informed about 
relevant research opportunities. The AWP Research and 
Development department will send a ‘Research Oppor-
tunity Letter’ on behalf of the research team to poten-
tial participants briefly explaining the study and what it 
involves. A researcher will telephone individuals who are 
interested in the study and answer any questions. If the 
individual is willing to take part, an eligibility assessment 
will be arranged.
Consent and baseline eligibility assessment
Individuals interested in taking part will be invited to 
a face- to- face appointment with a researcher to estab-
lish eligibility, answer questions about participation and 
obtain written informed consent.
The process of consenting young people (16 and 17 
years old) will follow the Department of Health Refer-
ence Guide to Consent19 and the Good Medical Practice 
Guidelines,20 which provide the guide that all health 
professionals need to take into account in obtaining 
consent. Although young people may be more vulnerable 
than adults, they are presumed to be able to give consent 
to their treatment. As in the case of adults, if young people 
decline to take part in the study their decision will be fully 
respected and accepted.
In order to establish eligibility, patients will be asked to 
complete the following scales:
 ► Life Events Checklist for DSM-5.21
 ► Childhood Trauma Questionnaire.22
 ► PCL-5.18
Those who are eligible will be asked to provide written 
informed consent for their participation in the trial and 
sociodemographic information. Additional baseline 
data will be collected using the following quantitative 
measures:
 ► Severity of psychotic symptoms: CAARMS,2 the Nega-
tive Scale of the Positive and Negative Syndrome Scale 
(PANSS),23 the Psychotic Symptom Rating Scales 
(PSYRATS)24 and the Community Assessment of 
Psychic Experiences (CAPE-42).25
 ► Severity of depression and anxiety: Patient Health 
Questionnaire (PHQ-9) for depression26 and Gener-
alized Anxiety Disorder Questionnaire (GAD-7) for 
anxiety.27
 ► Impaired functioning: Work and Social Adjustment 
Scale (WSAS).28
 ► Health status: Five- Level version of the EQ- 5D 
(EQ- 5D- 5L).29
 ► Drug use: the Drug Abuse Screening Test (DAST-10).30
Data will also be collected on medication use via self- 
report measures. The baseline eligibility assessment will 
last about 90 min.
Intervention: EMDR
Participants will receive up to 12 sessions of manualised, 
weekly, face- to- face EMDR therapy.31 Treatment has been 
manualised by EMDR consultants from Lancashire and 
South Cumbria Care NHS Foundation Trust (LSCFT) and 
individualised to target psychotic symptoms. The treat-
ment protocol was developed and evaluated through pilot 
cases with first- episode psychosis clients,32 and further 
refined as part of an ongoing feasibility RCT funded by 
the NIHR (PB- PG-0317-20037; ISRCTN43816889). Thera-
peutic sessions will be delivered by EMDR UK and Europe 
trained therapists who will receive training based on the 
LSCFT manual for the study. The training will be tailored 
to therapists’ needs, and will last between 4 and 8 hours. 
All EMDR therapists will have at least 1 year of experience 
of providing EMDR, and monthly supervision with an 
EMDR consultant will be in place. Each session will last 
approximately 90 min. The first two to four sessions will 
focus on establishing the therapeutic alliance, prepara-
tion for EMDR and stabilisation techniques, assessment 
and identification of targets, cognitions, emotions and 
bodily sensations. The following 8–10 sessions will focus 
on desensitisation, installation of positive cognitions and 
body scan for past, present and future stressful situations.
Written permission will be sought to audio record the 
therapeutic sessions. Ten per cent of the sessions will be 
randomly sampled and evaluated by accredited EMDR 
therapists independent of the study, to check treatment 
fidelity, using the EMDR fidelity checklist.33 Thera-
pists will be encouraged to liaise with participants’ care 
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coordinators as this could improve participants’ adher-
ence to therapy. If a serious adverse event (SAE) occurs 
in relation to therapy, or participant has difficulties 
engaging with therapy to the point where therapy is no 
longer worthwhile, the therapy will be discontinued.
Challenges to recruitment
The original feasibility study was designed as an RCT 
comparing EMDR with TAU. TAU in AWP is quite hetero-
geneous and consists of discharge back to the referrer, 
signposting to other services, CBT, family intervention 
or psychoeducation. Randomisation took place using a 
remote computerised randomisation service administered 
by the Bristol Trials Centre ensuring that allocations were 
concealed from the recruiting researcher. Randomisation 
was minimised by psychotic symptom severity (score on 
positive symptoms on CAARMS <11 or ≥11). However, 
following challenges to recruitment (described below), 
the study design was changed to a single- arm study.
During the first 7 months of the study (May to December 
2018), we only recruited three participants (against 
a target of 21). This poor recruitment was primarily 
because the number of patients identified as ARMS by the 
EI teams within AWP was much lower than expected, and 
only three of the six EI teams we originally planned to 
recruit from were able to support the study due to finan-
cial constraints to managing ARMS clients. Therefore, 
from July 2019, all participants recruited to the study were 
offered EMDR. Figure 1 shows the flow of participants in 
the randomised and single- arm phases of the trial.
Sample size and feasibility of recruitment
In the original protocol we had planned to recruit up 
to 40 participants. The initial sample size was informed 
by literature guidelines34 and pragmatic considerations 
concerning potential difficulties accessing this popula-
tion. The feasibility study would not be powered to detect 
important clinical differences between EMDR and TAU 
groups but would provide estimates of the completion 
and retention rates that would further assist in planning 
the recruitment for a future RCT.
Given the challenges with recruitment and modi-
fication of our study design (from a randomised to 
single- arm trial), we decreased our target sample size 
from 40 to 20 participants. This sample size will provide 
us with reasonable precision around estimates of percent-
ages completing the intervention and follow- ups. For 
example, if 70% of those who started EMDR complete the 
intervention, the 95% CIs would be 45% and 88%. Simi-
larly, if 75% of those who started EMDR are followed up 
to 12 months, the 95% CIs for the retention rate would 
be 50% and 91%.
Outcome assessment
The follow- up schedule will involve face- to- face assess-
ments at 4, 8 and 12 months after the baseline assess-
ment. Each follow- up assessment will last about 60 min. 
The primary outcome will be collected at 12 months of 
follow- up, and the secondary outcome at 4, 8 and 12 
months.
A 12- month follow- up will provide us with adequate 
data on retention rate that can be used to ensure that 
a definitive trial is adequately powered. If, in the defini-
tive trial, the intervention was shown to be effective at 12 
months, then further follow- up could examine whether 
effects are maintained over the longer term.
Primary outcome
 ► Transition to psychosis: ICD-10 diagnosis of psychotic 
disorder from clinical records or via the CAARMS.
Secondary outcome
 ► Severity of psychotic symptoms: CAARMS, PSYRATS, 
the Negative Scale of the PANSS and CAPE-42.
 ► Severity of PTSD symptoms: PCL-5.
 ► Severity of depression and anxiety: PHQ-9 and GAD-7.
 ► Impaired functioning: WSAS.
 ► Health status: EQ- 5D- 5L.
 ► Drug use: DAST-10.
Figure 1 Study flow chart for the feasibility trial (randomised and non- randomised components). EMDR, eye movement 
desensitisation and reprocessing; FU, follow- up; TAU, treatment as usual.
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 ► Medication use.
 ► Resource data use—we will ask questions about 
resource use including information on the use of 
primary and secondary care services, use of social 
services and disability payments received, time off 
school or work and productivity loss due to time off 
work or study.
If there are difficulties following up trial participants 
to obtain outcome data, researchers will prioritise collec-
tion of data on psychotic symptoms, PTSD symptoms and 
medication. Following the switch to single- arm design, it 
will no longer be possible to blind researchers to treat-
ment allocation in terms of avoiding potential bias in 
outcome measurement.
Quantitative data analysis
Quantitative data will be analysed in Stata V.15.35 If there 
are no differences in baseline characteristics of those who 
were randomised and those who enter the single- arm 
study, we will combine data to generate summary statistics 
on: (1) the proportion consenting to take part in the study; 
(2) the proportion completing the baseline assessment 
and agreeing to take part in the study; (3) the number of 
EMDR sessions attended and the proportion completing 
eight or more sessions (regarded as an adequate dose of 
therapy); (4) the proportion completing the follow- up 
assessments. Feasibility outcomes such as recruitment and 
retention rates will be calculated with 95% CIs using the 
exact binomial method.
We will also report the proportion of individuals who 
transitioned to psychosis at 12 months, and the CIs for 
the effect size will be calculated to assist the planning 
of a future RCT. We will also compare the continuous 
outcomes such as the severity of psychotic symptoms, 
depression, anxiety, PTSD symptoms and quality of life to 
show the frequency of data completion, mean and SD for 
the three time points.
Qualitative data collection
We will conduct in- depth individual interviews with all the 
therapists and participants who participate in the trial. In 
addition, up to 10 individuals who declined to take part 
in the trial will be interviewed to explore their views and 
understanding of the study and EMDR, and their reasons 
for declining to take part.
To encourage participation, and because well- planned 
interviews can gather the same material as those 
conducted face to face,36 therapists and study participants 
will be given the choice of being interviewed in person or 
over the telephone. Therapists will be interviewed within 
a month of finishing intervention delivery. The interviews 
will explore therapist views and experiences of delivering 
EMDR to patients with ARMS, how treatment could be 
better tailored to this patient group and what resources 
they would need if the intervention was evaluated in a 
large- scale RCT. The interviews will also be used to explore 
their views of the training and supervision received.
Interviews with participants who completed treatment 
or stopped early will explore their views and experi-
ences of the treatment received, identify how treatment 
delivery could be refined to increase its acceptability and 
how study materials could be improved. Participants who 
completed the study will be interviewed within a month 
of completing their 4- month follow- up, and those who 
stopped early will be interviewed within a month of doing 
so.
Topic guides will be developed for each set of inter-
views to ensure consistency across data collection. The 
therapist and study participant guides will be developed 
in parallel to ensure key areas are discussed with both 
practitioners and patients. This will help compare find-
ings across the interviews, highlighting similarities and 
differences between the views and experiences of patients 
and practitioners, and increasing the confidence with 
which study conclusions can be drawn. With interviewee 
consent, the interviews will be audio recorded and tran-
scribed verbatim.
Qualitative data analysis
All interviews will be fully transcribed and anonymised. 
Data collection and analysis will proceed in parallel, 
so that insights from earlier data can shape later data 
collection, and enable the team to establish when data 
saturation has been reached. The data gathered will be 
analysed thematically. Transcripts will be independently 
coded by different researchers, who will then meet to 
discuss their coding and interpretation of the data. This 
will help control for researcher bias and may lead to the 
coding frame being revised or defined more clearly. Tran-
scripts will then be imported into the software package 
NVivo V.1237 to allow electronic coding and retrieval 
of data. Once all the transcripts have been coded, data 
will be analysed using an approach similar to framework 
analysis.38
Additional qualitative work to address issues with recruitment 
and explore treatment options in ARMS populations
As the study progressed, to explore why recruitment had 
been so low, additional objectives were incorporated. 
These were:
1. To explore how potential patients with ARMS are iden-
tified and managed in primary and secondary care 
services.
2. To identify referral routes between primary and sec-
ondary care.
3. To explore other researchers’ experiences of recruit-
ing patients with ARMS to research studies in the UK.
This additional qualitative work will entail:
A. Interviews with general practitioners (GPs), clinicians 
from Primary Care Liaison Services and EI services.
B. Interviews with patients who did not participate in the 
interventional part of the study but who have been 
identified as ARMS by the EI teams we are recruiting 
from.
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C. Interviews with researchers who have been involved in 
recruiting patients with ARMS to research studies in 
the UK.
Summary of changes to the original feasibility study
There have been a number of changes to the original 
feasibility study. These are summarised below:
A. Change of study design from randomised trial to 
single- arm trial.
B. Decrease in sample size from 40 to 20 participants.
C. Change in the measure used to assess the severity of 
psychotic symptoms at baseline and follow- up assess-
ments from the Positive Scale of the PANSS to the 
CAARMS, as the latter is more sensitive.
D. Extending the time between patients being identified 
as ARMS to the time when they can be recruited into 
the study from 3 to 12 months.
E. Additional interviews with GPs, other clinicians from 
primary and secondary care services, patients with 
ARMS and researchers to better understand identi-
fication and management of patients with ARMS, in-
cluding routes into primary and secondary services.
Study management
Data management
Completed questionnaires will be stored securely in 
compliance with University of Bristol Data Security 
policies and the General Data Protection Regulation. 
Personal details will be entered onto a secure data-
base held on the University of Bristol server, and non- 
identifiable data will be entered onto a secure web- based 
database. Data collected on paper will be identifiable 
only by patient identification number. Information 
capable of identifying individuals will be held on the 
database with passwords restricted to authorised study 
staff only.
Data will be stored in the University of Bristol research 
data repository, and will be available on reasonable 
request.
Patient and public involvement
Patient and public involvement (PPI) played an important 
role in this study. This research idea was initially presented 
at a PPI event which brought together people with 
lived experiences of psychosis, their carers, clinicians, 
academics and commissioners. Further on, this idea was 
presented at the Hearing Voices Network, and through 
these contacts we established a PPI group who gave us 
important feedback on the research question, the inter-
vention and which measures to use. We anticipate that the 
group, which is still active, will: (1) ensure that the views 
of patients who have had a psychotic illness are heard at 
every stage of the study; (2) inform any developments 
of the intervention to make sure these are acceptable to 
the target population, (3) ensure patient documentation 
is easy to understand to maximise response and reten-
tion rates; and (4) help interpret and disseminate study 
findings.
MONITORING AND ADVERSE EVENTS
Adverse events
We use the recommendations for defining and reporting 
adverse events and harm as outlined by Parry et al.39 All 
SAEs will be reported to the chief investigator and the 
Trial Steering Committee (TSC). All SAEs of a related and 
unexpected nature will be reported to the main Research 
Ethics Committee (REC), in accordance with any proce-
dures of the sponsor. The decision to audit the trial rests 
with University Hospitals Bristol.
Trial oversight
A TSC will have independent oversight of the study, 
meeting at six monthly intervals during the course of the 
trial. The TSC will also take on data monitoring role for 
this feasibility study.
DISCUSSION
To our knowledge, this is the first study to investigate the 
feasibility of conducting a large RCT to establish whether 
EMDR could prevent the onset of psychosis in people 
with an ARMS. As psychotic illnesses usually occur in early 
adulthood and disrupt a key period of professional and 
social development, preventing psychosis would improve 
patients’ outcomes, and also decrease the substantial 
economic burden of this condition.
The results of this feasibility trial will provide us with 
a better understanding of this patient group, and will 
provide us with information that will be used to inform 
whether progression to a full trial would be feasible. 
The nested qualitative study will address issues of patient 
and therapist views of the intervention, and provide 
new insights into treatment pathways and experiences 
of this patient group. If shown to be feasible, a full- scale 
RCT will be conducted to examine the clinical and cost- 
effectiveness of EMDR to prevent the onset of psychosis 
in ARMS.
ETHICS AND DISSEMINATION
This protocol has been approved by South West- Cornwall 
and Plymouth REC (formerly South West- Exeter REC), 
Reference 18/SW/0037, 29.03.2018.
The results of this study will be disseminated through 
publications and conferences. Findings from this feasi-
bility trial will be published in psychiatry journals 
compliant with NIHR Open Access policy, and presented 
to clinical staff, service users and relevant clinical commis-
sioning groups.
Feasibility trial status
Recruitment to this study opened in May 2018, and closed 
in May 2020. At the time of writing (July 2020), 14 partic-
ipants have been recruited to the study. We expect to 
finish follow- up data collection by May 2021.
This article describes protocol version 4, dated 2 August 
2019. When all regulatory approvals had been received, 
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the protocol was version 1, dated 11 January 2018. 
Since then, two major amendments have been made 
with changes to incorporate additional qualitative work, 
decrease the sample size and change the study design 
from an RCT to a single- arm trial. The latter change took 
place in July 2019 prior to which we had recruited six 
participants.
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